---
title: "SURMOUNT-5: Tirzepatide Phase 3b Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/surmount-5
source: Primara Labs, markdown mirror of the HTML page
---

# SURMOUNT-5

In SURMOUNT-5, a phase 3b trial of tirzepatide in adults with obesity but without type 2 diabetes (n=751), mean body weight fell 20.2% on tirzepatide, maximum tolerated dose over 72 weeks, against 13.7% on semaglutide, maximum tolerated dose (Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5)).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

Tirzepatide Explained: SURMOUNT, SURPASS and Philippines Status1:58·[Transcript and chapters](https://www.primaralabs.com/videos/tirzepatide)

## Results

Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ.

## Side effects reported

SURMOUNT-5: The abstract does not name the estimand or give adverse event rates.

Design

## Trial design and sources

Compound

Tirzepatide

Phase

3b

Population

Adults with obesity but without type 2 diabetes

Participants randomised

751

Duration

72 weeks

Primary endpoint

Percent change in weight from baseline to week 72

Estimand

Not stated in the source read

Read out

11 May 2025

Head-to-head, open-label: tirzepatide (10 or 15 mg) against semaglutide (1.7 or 2.4 mg). The abstract does not name the estimand or give adverse event rates.

-   Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5) [open](https://doi.org/10.1056/NEJMoa2416394) · checked 23 September 2026
-   ClinicalTrials.gov NCT05822830 [open](https://clinicaltrials.gov/study/NCT05822830) · checked 23 September 2026
-   Registry: NCT05822830

Questions

## SURMOUNT-5, answered

### What did SURMOUNT-5 find?

In SURMOUNT-5, a phase 3b trial of tirzepatide in adults with obesity but without type 2 diabetes (n=751), mean body weight fell 20.2% on tirzepatide, maximum tolerated dose over 72 weeks, against 13.7% on semaglutide, maximum tolerated dose (Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5)).

### What side effects were reported in SURMOUNT-5?

SURMOUNT-5: The abstract does not name the estimand or give adverse event rates.

Related

## More on tirzepatide

-   [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5)
-   [SURMOUNT-1](https://www.primaralabs.com/research/trials/surmount-1)
-   [SURMOUNT-2](https://www.primaralabs.com/research/trials/surmount-2)
-   [SURMOUNT-3](https://www.primaralabs.com/research/trials/surmount-3)
-   [SURMOUNT-4](https://www.primaralabs.com/research/trials/surmount-4)
-   [Evidence Map: Tirzepatide](https://www.primaralabs.com/research/evidence#tirzepatide)
-   [Tirzepatide 15mg](https://www.primaralabs.com/marketplace/tirzepatide-15mg)